APIRx 1505 Flotex

APIRx 1505 Flotex is a preclinical cannabinoid-based pharmaceutical candidate being developed within the APIRx/Incannex portfolio for the treatment of gastroenterological disease, specifically Crohn’s disease.[1][3][5][6][7][9][12] It is one of multiple APIRx pipeline assets that apply proprietary cannabinoid formulations and delivery technologies toward inflammatory and gastrointestinal indications, but detailed public information on its exact active ingredient composition, delivery system, and molecular mechanism of action has not been disclosed.[1][3][5][6][7][9][12] The program is described in corporate materials as pre-clinical and “pre‑regulatory,” with planning for an initial Phase 1 clinical trial, indicating it remains at an early stage of development focused on establishing safety, pharmacokinetics, and proof of concept in Crohn’s disease.[1][3][5][6][7][9][12]